Preclinical Development SKLB 1206 , a Novel Orally Available Multikinase Inhibitor Targeting EGFR Activating and T 790 M Mutants , ErbB 2 , ErbB 4 , and VEGFR 2 , Displays Potent Antitumor Activity Both In Vitro and In Vivo